HRP20200690T1 - Agonisti triazola apj receptora - Google Patents

Agonisti triazola apj receptora Download PDF

Info

Publication number
HRP20200690T1
HRP20200690T1 HRP20200690TT HRP20200690T HRP20200690T1 HR P20200690 T1 HRP20200690 T1 HR P20200690T1 HR P20200690T T HRP20200690T T HR P20200690TT HR P20200690 T HRP20200690 T HR P20200690T HR P20200690 T1 HRP20200690 T1 HR P20200690T1
Authority
HR
Croatia
Prior art keywords
image
alkyl
methyl
pyridinyl
dimethoxyphenyl
Prior art date
Application number
HRP20200690TT
Other languages
English (en)
Inventor
Ning Chen
Xiaoqi Chen
Yinhong CHEN
Alan C. Cheng
Richard V. Connors
Jeffrey Deignan
Paul John Dransfield
Xiaohui Du
Zice Fu
Julie Anne Heath
Daniel B. Horne
Jonathan Houze
Matthew R. Kaller
Aarif Yusuf KHAKOO
David John Kopecky
Su-Jen Lai
Zhihua Ma
Lawrence R. Mcgee
Julio C. Medina
Jeffrey T Mihalic
Nobuko Nishimura
Steven H. Olson
Vatee Pattaropong
Gayathri Swaminath
Xiaodong Wang
Kevin Yang
Wen-Chen Yeh
Mikkel V. DEBENEDETTO
Robert P. Farrell
Simon J. HedleyEDLEY
Ted C Judd
Frank Kayser
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of HRP20200690T1 publication Critical patent/HRP20200690T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B57/00—Separation of optically-active compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Claims (30)

1. Spoj s Formulom I ili Formulom II: [image] [image] ili njegova farmaceutski prihvatljiva sol, njegov tautomer, farmaceutski prihvatljiva sol tautomera, stereoizomer bilo kojeg od prethodnih, ili njihova smjesa, naznačen time što: R1 je nesupstituirani piridil, piridonil, ili piridin N-oksid, ili je piridil, piridonil, ili piridin N-oksid supstituiran s 1, 2, 3, ili 4 supstituenata R1a; R1a u svakom slučaju je neovisno odabran od -F, -CI, -Br, -I, -CN, -C1-C6 alkil, -C1-C6 haloalkil, -C1-C6 perhaloalkil, -OH, -O-(C1-C6 alkil), -O-(C1-C6 haloalkil), -O-(C1-C6 perhaloalkil), -C2-C6 alkenil, -O-(C1-C6 alkil)-OH, -O-(C1-C6 alkil)-O-(C1-C6 alkil), -O-(C1-C6 haloalkil)-OH, -O-(C1-C6 haloalkil)-O-(C1-C6 alkil), -O-(C1-C6 perhaloalkil)-OH, -O-(C1-C6 perhaloalkil)-O-(C1-C6 alkil), -NH2, -NH(C1-C6 alkil), -N(C1-C6 alkil)2, -C(=O)-(C1-C6 alkil), -C(=O)OH, -C(=O)-O-(C1-C6 alkil), -C(=O)NH2, -C(=O)NH(C1-C6 alkil), -C(=O)N(C1-C6 alkil)2, fenil, -C(=O)-(heterociklil), ili heterociklil skupine, pri čemu heterociklil skupina od -C(=O)-(heterociklil) ili heterociklil skupina je 3 do 7 člani prsten koji sadrži 1, 2, ili 3 heteroatoma odabrana od N, O, ili S; R2 je odabran od -H, ili C1-C4 alkila ili je odsutan u spojevima s Formulom II; R3 je odabran od nesupstituiranog C1-C10 alkila, C1-C10 alkila supstituiranog s 1, 2, ili 3 supstituenta R3a, skupine s formulom -(CR3bR3c)-Q, skupine s formulom -NH-(CR3bR3c)-Q, skupine s formulom -(CR3bR3c)-C(=O)-Q, skupine s formulom -(CR3dR3e)-(CR3fR3g)-Q, skupine s formulom -(CR3b=CR3c)-Q, ili skupine s formulom -(heterociklil)-Q, pri čemu heterociklil od -(heterociklil)-Q ima 5 do 6 članova prstena od kojih 1, 2, ili 3 su heteroatomi odabrani od N, O, ili S i nesupstituiran je ili je supstituiran s 1, 2, ili 3 supstituenata R3h; R3a u svakom slučaju je neovisno odabran od -F, -CI, -CN, -OH, -O-(C1-C6 alkil),-O-(C1-C6 haloalkil), -O-(C1-C6 perhaloalkil), -O-(C1-C6 alkil)-OH, -O-(C1-C6 alkil)-O-(C1-C6 alkil), C2-C6 alkenil, C2-C6 alkinil, -NH2, -NH(C1-C6 alkil), ili -N(C1-C6 alkil)2; R3b i R3c su neovisno odabrani od -H, -F, -CI, -CN, -C1-C6 alkil, -C1-C6 haloalkil, -C1-C6 perhaloalkil, -OH, -O-(C1-C6 alkil), -O-(C1-C6 haloalkil), -O-(C1-C6 perhaloalkil), -O-(C1-C6 alkil)-OH, -O-(C1-C6 alkil)-O-(C1-C6 alkil), -NH2, -NH(C1-C6 alkil), ili -N(C1-C6 alkil)2; R3d i R3e su neovisno odabrani od -H, -F, -CI, -CN, -C1-C6 alkil, -C1-C6 haloalkil, -C1-C6 perhaloalkil, -OH, -O-(C1-C6 alkil), -O-(C1-C6 haloalkil), -O-(C1-C6 perhaloalkil), -O-(C1-C6 alkil)-OH, -O-(C1-C6 alkil)-O-(C1-C6 alkil), -NH2, -NH(C1-C6 alkil), ili -N(C1-C6 alkil)2; R3f i R3g su neovisno odabrani od -H, -F, -CI, -CN, -C1-C6 alkil, -C1-C6 haloalkil, -C1-C6 perhaloalkil, -OH, -O-(C1-C6 alkil), -O-(C1-C6 haloalkil), -O-(C1-C6 perhaloalkil), -O-(C1-C6 alkil)-OH, -O-(C1-C6 alkil)-O-(C1-C6 alkil), -NH2, -NH(C1-C6 alkil), ili -N(C1-C6 alkil)2; R3h u svakom slučaju je neovisno odabran od -F, -CI, -CN, -C1-C6 alkil, -C1-C6 haloalkil, -C1-C6 perhaloalkil, -OH, -O-(C1-C6 alkil), -O-(C1-C6 haloalkil), -O-(C1-C6 perhaloalkil), -O-(C1-C6 alkil)-OH, -O-(C1-C6 alkil)-O-(C1-C6 alkil), -NH2, -NH(C1-C6 alkil), -N(C1-C6 alkil)2, ili okso; Q je monociklička ili biciklička skupina C3-C10 aril, monociklička ili biciklička heteroarilna skupina s 5 do 10 članova prstena koji sadrže 1, 2, ili 3 heteroatoma odabrana od N, O, ili S, skupina C3-C8 cikloalkil, ili 3 do 7 člana heterociklil skupina koja sadrži 1, 2, ili 3 heteroatoma odabrana od N, O, ili S, pri čemu su skupina C6-C10 aril, skupina heteroaril, skupina cikloalkil, i skupina heterociklil nesupstituirane ili su supstituirane s 1, 2, 3, ili 4 supstituenata RQ; RQ u svakom slučaju je neovisno odabran od -F, -CI, -Br, -I, -CN, -C1-C6 alkil, -C1-C6 haloalkil, -C1-C6 perhaloalkil, -C2-C6 alkenil, -C2-C6 alkinil, -OH, -O-(C1-C6 alkil), -O-(C1-C6 haloalkil), -O-(C1-C6 perhaloalkil), -NH2, -NH(C1-C6 alkil), -N(C1-C6 alkil)2, -C(=O)-(C1-C6 alkil), -C(=O)OH, -C(=O)-O-(C1-C6 alkil), -C(=O)NH2, -C(=O)NH(C1-C6 alkil), -C(=O)N(C1-C6 alkil)2, -S(=O)2-(C1-C6 alkil), fenil, ili heteroarilne skupine, i Q heterociklil skupina može biti supstituirana s 1 okso RQ supstituentom; R4 je odabran od monocikličke ili bicikličke skupine C6-C10 aril, monocikličke ili bicikličke heteroarilne skupine s 5 do 10 članova prstena koji sadrže 1, 2, ili 3 heteroatoma neovisno odabranih od N, O, ili S, ili monocikličke ili bicikličke heterociklil skupine s 5 do 10 članova prstena koji sadrže 1, 2, 3, ili 4 heteroatoma neovisno odabranih od N, O, ili S, pri čemu su skupina C6-C10 aril, heteroarilna skupina, ili heterociklil skupina nesupstituirane ili su supstituirane s 1, 2, ili 3 supstituenta R4a; R4a u svakom slučaju je neovisno odabran od -F, -CI, -Br, -I, -CN, -C1-C6 alkil, -C1-C6 haloalkil, -C1-C6 perhaloalkil, -OH, -O-(C1-C6 alkil), -O-(C1-C6 haloalkil), -O-(C1-C6 perhaloalkil), -NH2, -NH(C1-C6 alkil), -N(C1-C6 alkil)2, -C(=O)-(C1-C6 alkil), -C(=O)OH, -C(=O)-O-(C1-C6 alkil), -C(=O)NH2, -C(=O)NH(C1-C6 alkil), ili -C(=O)N(C1-C6 alkil)2, i heterociklil R4 skupina može biti dalje supstituirana s 1 okso supstituentom; i dodatno pri čemu: ako je R4 nesupstituirani ili supstituirani fenilni prsten i R3 je skupina s formulom -(CR3b=CR3c)-Q, tada je najmanje jedno od sljedećih istinito: a) R4 je supstituiran s najmanje jednom skupinom -O-(C1-C6 alkil); b) Q nije oksadiazol; c) R3b nije -H; d) R3c nije -H; e) R1 nije skupina 2-piridil; ili f) R4 je supstituiran s dvije ili više skupina -O-(C1-C6 alkil).
2. Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, stereoizomer bilo kojeg od prethodnih, ili njihova smjesa, naznačen time što R1 je nesupstituirani piridil ili je piridil supstituiran s 1 ili 2 R1a supstituenata.
3. Spoj prema patentnom zahtjevu 2 ili njegova farmaceutski prihvatljiva sol, stereoizomer bilo kojeg od prethodnih, ili njihova smjesa, naznačen time što R1a u svakom slučaju je neovisno odabran od -CH3, -CH2CH3, -F, -Cl, -Br, -CN,-CF3, -CH=CH2, -C(=O)NH2, -C(=O)NH(CH3), -C(=O)N(CH3)2, -C(=O)NH(CH2CH3), -OH, -OCH3,-OCHF2, -OCH2CH3, -OCH2CF3, -OCH2CH2OH, -OCH2C(CH3)2OH,-OCH2C(CF3)2OH, -OCH2CH2OCH3, -NH2, -NHCH3, -N(CH3)2, fenil, ili skupine s formulom [image] pri čemu simbol [image] , kada se povuče preko veze, označava točku vezanja na ostatak molekule.
4. Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, stereoizomer bilo kojeg od prethodnih, ili njihova smjesa, naznačen time što je R1 odabran od [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] pri čemu simbol [image] , kada se povuče preko veze, označava točku vezanja na ostatak molekule.
5. Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, stereoizomer bilo kojeg od prethodnih, ili njihova smjesa, naznačen time što je R1 odabran od [image] [image] [image] pri čemu simbol [image] , kada se povuče preko veze, označava točku vezanja na ostatak molekule.
6. Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, stereoizomer bilo kojeg od prethodnih, ili njihova smjesa, naznačen time što R2 je -H.
7. Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, stereoizomer bilo kojeg od prethodnih, ili njihova smjesa, naznačen time što R4 je fenil, piridil, pirimidinil, izoksazolil, indolil, ili naftil bilo koji od njih može biti nesupstituiran ili supstituiran s 1, 2, ili 3 supstituenta R4a.
8. Spoj prema patentnom zahtjevu 7 ili njegova farmaceutski prihvatljiva sol, stereoizomer bilo kojeg od prethodnih, ili njihova smjesa, naznačen time što je R4a u svakom slučaju neovisno odabran od -CH3, -F, -CI, -Br, -CN, -CF3, -OCH3, -OCHF2, -OCH2CH3, -C(=O)OCH3, -C(=O)CH3, ili -N(CH3)2.
9. Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, stereoizomer bilo kojeg od prethodnih, ili njihova smjesa, naznačen time što je R4 odabran od [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] ili [image] pri čemu simbol [image] , kada se povuče preko veze, označava točku vezanja na ostatak molekule.
10. Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, stereoizomer bilo kojeg od prethodnih, ili njihova smjesa, naznačen time što R4 je fenil supstituiran s 1 ili 2 supstituenta R4a, pri čemu su R4a supstituenti skupine -O-(C1-C2 alkil).
11. Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, stereoizomer bilo kojeg od prethodnih, ili njihova smjesa, naznačen time što Q je monociklička heteroarilna skupina s 5 ili 6 članova prstena koji sadrže 1 ili 2 heteroatoma odabrana od N, O, ili S i Q je nesupstituiran ili je supstituiran s 1 ili 2 supstituenta RQ.
12. Spoj prema patentnom zahtjevu 11 ili njegova farmaceutski prihvatljiva sol, stereoizomer bilo kojeg od prethodnih, ili njihova smjesa, naznačen time što Q je pirimidinil ili piridil skupina i Q je nesupstituiran ili je supstituiran s 1 ili 2 supstituenta RQ.
13. Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, stereoizomer bilo kojeg od prethodnih, ili njihova smjesa, naznačen time što Q je odabran od [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] ili pri čemu simbol [image] , kada se povuče preko veze, označava točku vezanja na ostatak molekule.
14. Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, stereoizomer bilo kojeg od prethodnih, ili njihova smjesa, naznačen time što je R3 skupina s formulom -(CR3dR3e)-(CR3fR3g)-Q.
15. Spoj prema patentnom zahtjevu 14 ili njegova farmaceutski prihvatljiva sol, stereoizomer bilo kojeg od prethodnih, ili njihova smjesa, naznačen time što R3 ima formulu [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] pri čemu simbol [image] , kada se povuče preko veze, označava točku vezanja na ostatak molekule.
16. Spoj prema patentnom zahtjevu 15 ili njegova farmaceutski prihvatljiva sol, stereoizomer bilo kojeg od prethodnih, ili njihova smjesa, naznačen time što R3 ima formulu [image] [image] [image] [image] pri čemu simbol [image] , kada se povuče preko veze, označava točku vezanja na ostatak molekule.
17. Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, stereoizomer bilo kojeg od prethodnih, ili njihova smjesa, naznačen time što je spoj (1R,2S)-N-(4-(2,6-dimetoksifenil)-5-(6-metoksi-2-piridinil)-4H-1,2,4-triazol-3-il)-1-metoksi-1-(5-metil-2-pirimidinil)-2-propansulfonamid; (2S,3R)-N-(4-(2,6-dimetoksifenil)-5-(5-metil-3-piridinil)-4H-1,2,4-triazol-3-il)-3-(5-metil-2-pirimidinil)-2-butansulfonamid; (1R,2S)-N-(4-(2,6-dimetoksifenil)-5-(5-metil-3-piridinil)-4H-1,2,4-triazol-3-il)-1-metoksi-1-(5-metil-2-pirimidinil)-2-propansulfonamid; (1R,2S)-N-(4-(2,6-dimetoksifenil)-5-(5-metil-3-piridinil)-4H-1,2,4-triazol-3-il)-1-hidroksi-1-(5-metil-2-pirimidinil)-2-propansulfonamid; (1S,2R)-1-(5-kloro-2-pirimidinil)-N-(4-(2,6-dimetoksifenil)-5-(5-metil-3-piridinil)-4H-1,2,4-triazol-3-il)-1-metoksi-2-propansulfonamid; (1S,2R)-N-(4-(2,6-dimetoksifenil)-5-(5-metil-3-piridinil)-4H-1,2,4-triazol-3-il)-1-metoksi-1-(5-metil-2-pirazinil)-2-propansulfonamid; (1R,2S)-N-(4-(2,6-dimetoksifenil)-5-(5-metil-3-piridinil)-4H-1,2,4-triazol-3-il)-1-hidroksi-1-(5-metil-2-pirazinil)-2-propansulfonamid; (1R,2S)-N-(4-(2,6-dimetoksifenil)-5-(3-piridinil)-4H-1,2,4-triazol-3-il)-1-metoksi-1-(5-metil-2-pirimidinil)-2-propansulfonamid; (2S,3R)-N-(4-(2,6-dimetoksifenil)-5-(3-piridinil)-4H-1,2,4-triazol-3-il)-3-(5-metil-2-pirimidinil)-2-butansulfonamid; (1R,2S)-1-(5-kloro-2-pirimidinil)-N-(4-(2,6-dimetoksifenil)-5-(3-piridinil)-4H-1,2,4-triazol-3-il)-1-etoksi-2-propansulfonamid; (1R,2S)-N-(4-(2,6-dimetoksifenil)-5-(5-metil-3-piridinil)-4H-1,2,4-triazol-3-il)-1-etoksi-1-(5-metil-2-pirimidinil)-2-propansulfonamid; (1S,2R)-N-(4-(2,6-dimetoksifenil)-5-(3-piridinil)-4H-1,2,4-triazol-3-il)-1-metoksi-1-(5-metil-2-pirazinil)-2-propansulfonamid; (1R,2S)-N-(4-(2,6-dimetoksifenil)-5-(6-metil-2-piridinil)-4H-1,2,4-triazol-3-il)-1-hidroksi-1-(5-metil-2-pirimidinil)-2-propansulfonamid; (1R,2S)-N-(4-(2,6-dimetoksifenil)-5-(3-piridinil)-4H-1,2,4-triazol-3-il)-1-etoksi-1-(5-metil-2-pirimidinil)-2-propansulfonamid; (1R,2S)-N-(4-(2,6-dimetoksifenil)-5-(5-metil-3-piridinil)-4H-1,2,4-triazol-3-il)-1-(5-fluoro-2-pirimidinil)-1-metoksi-2-propansulfonamid; (2S,3R)-N-(4-(2,6-dimetoksifenil)-5-(5-metil-3-piridinil)-4H-1,2,4-triazol-3-il)-3-(5-metil-2-pirazinil)-2-butansulfonamid; (1R,2S)-N-(4-(2,6-dimetoksifenil)-5-(3-piridinil)-4H-1,2,4-triazol-3-il)-1-etoksi-1-(5-fluoro-2-pirimidinil)-2-propansulfonamid; (1S,2S)-N-(4-(2,6-dimetoksifenil)-5-(5-metil-3-piridinil)-4H-1,2,4-triazol-3-il)-1-(1-metiletoksi)-1-(5-metil-2-pirimidinil)-2-propansulfonamid; (1R,2S)-N-(4-(2,6-dimetoksifenil)-5-(5-metil-3-piridinil)-4H-1,2,4-triazol-3-il)-1-(1-metiletoksi)-1-(5-metil-2-pirimidinil)-2-propansulfonamid; (1S,2R)-1-(5-kloro-2-pirimidinil)-N-(4-(2,6-dimetoksifenil)-5-(3-piridinil)-4H-1 ,2,4-triazol-3-il)-1-metoksi-2-propansulfonamid; (1R,2S)-N-(4-(2,6-dimetoksifenil)-5-(5-metil-3-piridinil)-4H-1,2,4-triazol-3-il)-1-metoksi-1-(5-metoksi-2-pirazinil)-2-propansulfonamid; (2S,3R)-N-(4-(2,6-dimetoksifenil)-5-(3-piridinil)-4H-1,2,4-triazol-3-il)-3-(5-metil-2-pirazinil)-2-butansulfonamid; (1R,2S)-N-(4-(2,6-dimetoksifenil)-5-(5-metil-3-piridinil)-4H-1,2,4-triazol-3-il)-1-etoksi-1-(5-fluoro-2-pirimidinil)-2-propansulfonamid; (1R,2S)-N-(4-(4,6-dimetoksi-5-pirimidinil)-5-(6-metoksi-2-piridinil)-4H-1,2,4-triazol-3-il)-1-metoksi-1-(5-metil-2-pirimidinil)-2-propansulfonamid; (1R,2R)-1-(5-kloro-2-pirimidinil)-N-(4-(2,6-dimetoksifenil)-5-(3-piridinil)-4H-1 ,2,4-triazol-3-il)-1-etoksi-2-propansulfonamid; ili (1S,2S)-N-(4-(2,6-dimetoksifenil)-5-(5-metil-3-piridinil)-4H-1,2,4-triazol-3-il)-1-etoksi-1-(5-metil-2-pirimidinil)-2-propansulfonamid.
18. Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, stereoizomer bilo kojeg od prethodnih, ili njihova smjesa, naznačen time što je spoj (1R,2S)-N-(4-(2,6-dimetoksifenil)-5-(6-metoksi-2-piridinil)-4H-1 ,2,4-triazol-3-il)-1-metoksi-1-(5-metil-2-pirimidinil)-2-propansulfonamid.
19. Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, stereoizomer bilo kojeg od prethodnih, ili njihova smjesa, naznačen time što je spoj (2S,3R)-N-(4-(2,6-dimetoksifenil)-5-(5-metil-3-piridinil)-4H-1,2,4-triazol-3-il)-3-(5-metil-2-pirimidinil)-2-butansulfonamid.
20. Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, stereoizomer bilo kojeg od prethodnih, ili njihova smjesa, naznačen time što je spoj (1R,2S)-N-(4-(2,6-dimetoksifenil)-5-(3-piridinil)-4H-1,2,4-triazol-3-il)-1-etoksi-1-(5-fluoro-2-pirimidinil)-2-propansulfonamid.
21. Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, stereoizomer bilo kojeg od prethodnih, ili njihova smjesa, naznačen time što je spoj (1S,2S)-N-(4-(2,6-dimetoksifenil)-5-(5-metil-3-piridinil)-4H-1,2,4-triazol-3-il)-1-(1-metiletoksi)-1-(5-metil-2-pirimidinil)-2-propansulfonamid.
22. Farmaceutski pripravak, naznačen time što sadrži spoj prema bilo kojem od patentnih zahtjeva 1-21 ili njegova farmaceutski prihvatljiva sol, stereoizomer bilo kojeg od prethodnih, ili njihova smjesa, i najmanje jedno farmaceutski prihvatljivo pomoćno sredstvo, nosač ili razrjeđivač.
23. Farmaceutski pripravak prema patentnom zahtjevu 22, naznačen time što nadalje sadrži terapeutsko sredstvo odabrano od α-blokatora, β-blokatora, inhibitora angiotenzin konvertirajućeg enzima (ACE), blokatora angiotenzin-receptora (ARB, blokatora kalcijevih kanala, diuretika, inhibitora hiperpolarizacijske struje, aktivatora miozina, ili inhibitora neutralne endopeptidaze (NEP).
24. Spoj prema bilo kojem od patentnih zahtjeva 1-21 ili njegova farmaceutski prihvatljiva sol, stereoizomer bilo kojeg od prethodnih, ili njihova smjesa, ili farmaceutski pripravak prema patentnom zahtjevu 22 naznačen time što je za uporabu za liječenje kardiovaskularnog stanja.
25. Spoj za uporabu prema patentnom zahtjevu 24, naznačen time što je kardiovaskularno stanje zatajenje srca.
26. Spoj za uporabu prema patentnom zahtjevu 24, naznačen time što je kardiovaskularno stanje zatajenje srca sa smanjenom ejekcijskom frakcijom.
27. Spoj za uporabu prema patentnom zahtjevu 24, naznačen time što je kardiovaskularno stanje zatajenje srca s očuvanom ejekcijskom frakcijom.
28. Spoj za uporabu prema patentnom zahtjevu 24, naznačen time što je kardiovaskularno stanje akutno zatajenje srca.
29. Spoj za uporabu prema patentnom zahtjevu 24, naznačen time što je kardiovaskularno stanje hipertenzija.
30. Spoj prema bilo kojem od patentnih zahtjeva 1-21 ili njegova farmaceutski prihvatljiva sol, stereoizomer bilo kojeg od prethodnih, ili njihova smjesa, ili farmaceutski pripravak prema patentnom zahtjevu 22 naznačen time što je za upotrebu u liječenju stanja gdje je poželjno aktivirati APJ receptor, pri čemu je stanje pretilost, dijabetes, dijabetička nefropatija ili kronična bolest bubrega.
HRP20200690TT 2015-05-20 2020-04-29 Agonisti triazola apj receptora HRP20200690T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562164106P 2015-05-20 2015-05-20
PCT/US2016/033088 WO2016187308A1 (en) 2015-05-20 2016-05-18 Triazole agonists of the apj receptor
EP16730076.3A EP3300500B9 (en) 2015-05-20 2016-05-18 Triazole agonists of the apj receptor

Publications (1)

Publication Number Publication Date
HRP20200690T1 true HRP20200690T1 (hr) 2020-07-24

Family

ID=56134572

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20200690TT HRP20200690T1 (hr) 2015-05-20 2020-04-29 Agonisti triazola apj receptora

Country Status (38)

Country Link
US (10) US9573936B2 (hr)
EP (1) EP3300500B9 (hr)
JP (3) JP6356364B1 (hr)
KR (1) KR102653667B1 (hr)
CN (1) CN108137545B (hr)
AR (1) AR104716A1 (hr)
AU (1) AU2016263564B2 (hr)
BR (1) BR112017024618B1 (hr)
CA (1) CA2985542C (hr)
CL (1) CL2017002922A1 (hr)
CO (1) CO2017012991A2 (hr)
CY (1) CY1123451T1 (hr)
DK (1) DK3300500T3 (hr)
EA (1) EA034776B1 (hr)
ES (1) ES2791315T3 (hr)
HK (1) HK1253366A1 (hr)
HR (1) HRP20200690T1 (hr)
HU (1) HUE050317T2 (hr)
IL (1) IL255459A (hr)
JO (1) JO3653B1 (hr)
LT (1) LT3300500T (hr)
MA (1) MA42145B1 (hr)
ME (1) ME03733B (hr)
MX (1) MX2017014818A (hr)
MY (1) MY193818A (hr)
NZ (1) NZ737004A (hr)
PE (1) PE20180529A1 (hr)
PH (1) PH12017502107A1 (hr)
PL (1) PL3300500T3 (hr)
PT (1) PT3300500T (hr)
RS (1) RS60353B1 (hr)
SI (1) SI3300500T1 (hr)
TN (1) TN2017000483A1 (hr)
TW (1) TWI606039B (hr)
UA (1) UA119932C2 (hr)
UY (1) UY36684A (hr)
WO (1) WO2016187308A1 (hr)
ZA (1) ZA201707706B (hr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1143120A (ja) * 1997-07-28 1999-02-16 Ishikawajima Harima Heavy Ind Co Ltd 容器の後処理装置
HUE050317T2 (hu) * 2015-05-20 2020-11-30 Amgen Inc APJ receptor triazol agonistái
ES2739526T3 (es) 2015-06-03 2020-01-31 Bristol Myers Squibb Co Agonistas de APJ de 4-hidroxi-3-(heteroaril)piridin-2-ona para su uso en el tratamiento de trastornos cardiovaculares
CN108368087B (zh) 2015-10-14 2022-04-12 百时美施贵宝公司 作为apj激动剂的2，4-二羟基-烟酰胺
EP3433247B1 (en) 2016-03-24 2021-09-08 Bristol-Myers Squibb Company 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
WO2018093577A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
MA46824A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole substitués par alkyle en tant qu'agonistes du récepteur apj
EP3541805B1 (en) 2016-11-16 2020-10-14 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
WO2018093580A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
US10736883B2 (en) 2016-11-16 2020-08-11 Amgen Inc. Triazole furan compounds as agonists of the APJ receptor
WO2018093579A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
US11773058B2 (en) * 2017-08-15 2023-10-03 Inflazome Limited Sulfonamide carboxamide compounds
EP3704122B1 (en) 2017-11-03 2021-09-01 Amgen Inc. Fused triazole agonists of the apj receptor
EP3759095A1 (en) * 2018-03-01 2021-01-06 Annapurna Bio Inc. Compounds and compositions for treating conditions associated with apj receptor activity
US11807624B2 (en) 2018-05-01 2023-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the APJ receptor
CN108728408B (zh) * 2018-05-28 2021-08-24 天津博雅秀岩生物技术有限公司 犬胎膜间充质干细胞及制备方法和使用的培养基
CN108795853B (zh) * 2018-05-28 2021-08-24 天津博雅秀岩生物技术有限公司 制备犬胎膜间充质干细胞的方法和犬胎膜间充质干细胞
EP4319873A1 (en) * 2021-04-06 2024-02-14 Bioage Labs, Inc. Apelin receptor modulators for treating age-related muscle conditions
WO2024072907A1 (en) 2022-09-27 2024-04-04 BioAge Labs, Inc. Apelin receptor agonists for treating muscle conditions
CN117417325A (zh) * 2023-12-19 2024-01-19 药康众拓(北京)医药科技有限公司 氘代1,2,4-***类Apelin受体激动剂药物及用途

Family Cites Families (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4681943A (en) * 1984-11-30 1987-07-21 The Dow Chemical Company 1-acyl-1-(2-pyridinyl)semicarbazides
JPS62149673A (ja) * 1985-09-05 1987-07-03 Sumitomo Chem Co Ltd ピリジン誘導体、その製造法およびそれを有効成分とする植物病害防除剤
DE3825867A1 (de) 1988-03-04 1989-09-14 Bayer Ag Heterocyclisch substituierte sulfonylaminoazole und ihre verwendung als herbizide
EP0409332A3 (en) 1989-07-19 1991-08-07 Merck & Co. Inc. Substituted triazoles as angiotensin ii antagonists
DE3928605A1 (de) 1989-08-30 1991-03-07 Bayer Ag Substituierte sulfonylaminoazole
CA2075639A1 (en) 1990-02-13 1991-08-14 William J. Greenlee Triazole angiotensin ii antagonists incorporating a substituted benzyl element
JPH0511439A (ja) 1990-09-13 1993-01-22 Fuji Photo Film Co Ltd 光重合性組成物
DE4035141A1 (de) 1990-11-06 1992-05-07 Bayer Ag Substituierte sulfonylaminotriazolylpyrimidine
SK278998B6 (sk) 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
SE9103397D0 (sv) 1991-11-18 1991-11-18 Kabi Pharmacia Ab Nya substituerade salicylsyror
JP3217846B2 (ja) * 1992-03-04 2001-10-15 クミアイ化学工業株式会社 トリアゾール誘導体及び殺虫剤
ATE205202T1 (de) 1992-03-13 2001-09-15 Merck Sharp & Dohme Imidazol-, triazol- und tetrazolderivate
US5411839A (en) 1993-01-15 1995-05-02 Eastman Kodak Company Image formation in color reversal materials using strong inhibitors
ES2163004T3 (es) 1995-02-03 2002-01-16 Upjohn Co Feniloxazolidinona sustituida por un anillo heteroaromatico como agente antimicrobiano.
US5563026A (en) 1995-04-28 1996-10-08 Eastman Kodak Company Color negative element having improved green record printer compatibility
DE19725450A1 (de) 1997-06-16 1998-12-17 Hoechst Schering Agrevo Gmbh 4-Haloalkyl-3-heterocyclylpyridine und 4-Haloalkyl-5-heterocyclylpyrimidine, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel
JP3788676B2 (ja) 1997-11-11 2006-06-21 富士写真フイルム株式会社 有機エレクトロルミネツセンス素子材料およびそれを使用した有機エレクトロルミネツセンス素子
NZ506292A (en) 1998-02-13 2003-05-30 Upjohn Co Substituted aminophenyl isoxazoline methylamide derivatives useful as antimicrobials
JP2002504550A (ja) 1998-02-25 2002-02-12 ファルマシア・アンド・アップジョン・カンパニー 抗微生物剤として有用な置換アミノメチルイソオキサゾリン誘導体
PL355639A1 (en) 1999-09-10 2004-05-04 Merck & Co, Inc. Tyrosine kinase inhibitors
EP1265921B1 (en) 2000-03-16 2007-05-23 Genesoft, Inc. Charged compounds comprising a nucleic acid binding moiety and uses therefor
DE60119714T2 (de) 2000-03-23 2006-09-07 Takeda Chemical Industries, Ltd. Peptidderivat
BR0110961A (pt) 2000-05-19 2004-06-29 Merck Patent Gmbh Derivados de triazol
WO2002053160A1 (en) 2000-12-29 2002-07-11 Alteon, Inc. Method for treating glaucoma ivb
WO2002053101A2 (en) 2000-12-29 2002-07-11 Alteon, Inc. Method for treating fibrotic diseases or other indications
CA2445568A1 (en) * 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Triazole-derived kinase inhibitors and uses thereof
US6787555B2 (en) 2001-04-30 2004-09-07 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
US6727364B2 (en) 2001-04-30 2004-04-27 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
US6790846B2 (en) 2001-05-24 2004-09-14 The Procter & Gamble Company Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity
JP2003005356A (ja) 2001-06-20 2003-01-08 Fuji Photo Film Co Ltd 電子線又はｘ線用ネガ型レジスト組成物
DE10138569A1 (de) 2001-08-06 2003-04-30 Bayer Ag Regulation des APJ-Rezeptors
JP2003321456A (ja) 2002-04-30 2003-11-11 Fuji Photo Film Co Ltd ５−アミノ−４−含窒素芳香族ヘテロ環置換ピラゾール類の製造方法
AU2003295324B2 (en) 2002-08-23 2008-08-28 Ardea Biosciences,Inc. Non-nucleoside reverse transcriptase inhibitors
US7084145B2 (en) 2002-10-25 2006-08-01 Pfizer Inc. Triazole compounds useful in therapy
US7361669B2 (en) 2003-01-02 2008-04-22 Millennium Pharmaceuticals, Inc. Compositions and method for inhibiting TGF-β
US20040167188A1 (en) 2003-02-14 2004-08-26 Zhili Xin Protein-tyrosine phosphatase inhibitors and uses thereof
US7169797B2 (en) 2003-02-14 2007-01-30 Abbott Laboratories Protein-tyrosine phosphatase inhibitors and uses thereof
US20050170431A1 (en) 2003-02-28 2005-08-04 Plexxikon, Inc. PYK2 crystal structure and uses
WO2005004818A2 (en) 2003-07-09 2005-01-20 Imclone Systems Incorporated Heterocyclic compounds and their use as anticancer agents
EP1664052B1 (en) 2003-08-15 2009-02-18 AstraZeneca AB Fused heterocycles as inhibitors of glutamate racemase (muri)
JP2007509045A (ja) 2003-10-18 2007-04-12 バイエル・ヘルスケア・アクチェンゲゼルシャフト 尿失禁および関連疾患の処置用のｇａｂａアゴニストとしての５−置換２−（フェニルメチル）チオ−４−フェニル−４ｈ−１，２，４−トリアゾール誘導体および関連化合物
JP2005170939A (ja) 2003-11-20 2005-06-30 Takeda Chem Ind Ltd 糖尿病の予防・治療剤
US20050165015A1 (en) 2004-01-23 2005-07-28 Ncube Mghele V. Vanilloid receptor ligands and their use in treatments
US7297168B2 (en) 2004-02-02 2007-11-20 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
DE102004008141A1 (de) 2004-02-19 2005-09-01 Abbott Gmbh & Co. Kg Guanidinverbindungen und ihre Verwendung als Bindungspartner für 5-HT5-Rezeptoren
AU2005230867A1 (en) 2004-03-26 2005-10-20 Amphora Discovery Corporation Certain triazole-based compounds, compositions, and uses thereof
JP2008502687A (ja) 2004-06-14 2008-01-31 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
US7399317B2 (en) 2004-08-26 2008-07-15 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
WO2006030805A1 (ja) 2004-09-16 2006-03-23 Astellas Pharma Inc. トリアゾール誘導体またはその塩
JP4954083B2 (ja) 2004-11-18 2012-06-13 シンタ ファーマスーティカルズ コーポレイション Ｈｓｐ９０活性を調節するトリアゾール化合物
US20060156480A1 (en) 2005-01-14 2006-07-20 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
JPWO2006080533A1 (ja) 2005-01-31 2008-06-19 持田製薬株式会社 ３−アミノ−１，２，４−トリアゾール誘導体
US8399464B2 (en) 2005-03-09 2013-03-19 Nippon Kayaku Kabushiki Kaisha HSP90 inhibitor
CN101160291B (zh) 2005-03-09 2012-09-05 日本化药株式会社 作为hsp90抑制剂的***衍生物
JP2008533193A (ja) 2005-03-21 2008-08-21 ファイザー・リミテッド オキシトシン拮抗薬としての置換トリアゾール誘導体
AU2006235759B2 (en) 2005-04-06 2011-07-28 Msd K.K. 1,4-substituted piperazine derivative
WO2007007688A1 (ja) 2005-07-08 2007-01-18 Mochida Pharmaceutical Co., Ltd. ３,５－ジアミノ－１,２,４－トリアゾール誘導体
US7615569B2 (en) 2005-08-16 2009-11-10 Icagen, Inc. Inhibitors of ion channels
US8921406B2 (en) 2005-08-21 2014-12-30 AbbVie Deutschland GmbH & Co. KG 5-ring heteroaromatic compounds and their use as binding partners for 5-HT5 receptors
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
JP5525812B2 (ja) 2006-04-19 2014-06-18 メルク セローノ ソシエテ アノニム Ｍｅｋインヒビターとしての新規ヘテロアリール置換アリールアミノピリジン誘導体
WO2007139967A2 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
AU2012200157B2 (en) 2006-05-25 2014-08-21 Synta Pharmaceuticals Corp. Method for treating proliferative disorders associated with protooncogene products
EP2034996A2 (en) 2006-05-25 2009-03-18 Synta Pharmaceuticals Corporation Triazole compounds that modulate hsp90 activity
TW200806637A (en) 2006-05-25 2008-02-01 Synta Pharmaceuticals Corp Synthesis of triazole compounds that modulate HSP90 activity
AU2007267803B2 (en) 2006-05-25 2011-08-25 Synta Pharmaceuticals Corp. Method for treating non-Hodgkin's lymphoma
US8034834B2 (en) 2006-05-25 2011-10-11 Synta Pharmaceuticals Corp. Method for treating proliferative disorders with HSP90 inhibitors
CN101541783B (zh) 2006-06-30 2014-10-01 苏尼西斯制药有限公司 吡啶酮基pdk1抑制剂
CN101511800B (zh) 2006-07-14 2013-02-27 坎莫森特里克斯公司 ***基苯基苯磺酰胺
US7718683B2 (en) 2006-07-14 2010-05-18 Chemocentryx, Inc. Triazolyl phenyl benzenesulfonamides
AU2007284537B2 (en) 2006-08-17 2012-04-12 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
US20110046125A1 (en) 2006-10-19 2011-02-24 Synta Pharmaceuticals Corp. Method for treating infections
US20100280032A1 (en) 2006-10-26 2010-11-04 Synta Pharmaceuticals Corp. Method for treating inflammatory disorders
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
PL2118077T3 (pl) 2007-02-08 2015-05-29 Synta Pharmaceuticals Corp Związki triazolowe modulujące aktywność hsp90
US7909187B2 (en) 2007-02-20 2011-03-22 Lonzell Montgomery Modular baby bottle system
WO2008112199A1 (en) 2007-03-12 2008-09-18 Synta Pharmaceuticals Corp. Method for inhibiting topoisomerase ii
WO2008153730A2 (en) 2007-05-25 2008-12-18 Synta Pharmaceuticals Corp. Method for treating proliferative disorders associated with mutations in c-met
ES2617305T3 (es) 2007-07-17 2017-06-16 Acea Biosciences, Inc. Compuestos heterocíclicos y usos como agentes anticancerosos
TWI438199B (zh) 2007-08-13 2014-05-21 Synta Pharmaceuticals Corp 調控ｈｓｐ９０活性的***化合物
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
WO2009075890A2 (en) 2007-12-12 2009-06-18 Synta Pharmaceuticals Corp. Method for synthesis of triazole compounds that modulate hsp90 activity
PE20091268A1 (es) 2007-12-19 2009-09-19 Amgen Inc Derivados heterociclicos como inhibidores de pi3 quinasa
DE102008013587A1 (de) 2008-03-11 2009-09-17 Bayer Schering Pharma Aktiengesellschaft Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung
EP2103602A1 (en) 2008-03-17 2009-09-23 AEterna Zentaris GmbH Novel 1,2,4-triazole derivatives and process of manufacturing thereof
CN102056483A (zh) 2008-06-03 2011-05-11 西佳技术公司 用于治疗或预防登革病毒感染的小分子抑制剂
US8492427B2 (en) 2008-07-01 2013-07-23 Genentech, Inc. Isoindolones derivatives as MEK kinase inhibitors and methods of use
PE20110570A1 (es) 2008-07-01 2011-08-26 Genentech Inc Heterociclos biciclicos sustituidos
US20100031237A1 (en) 2008-08-01 2010-02-04 International Business Machines Corporation Methods for Detecting Inter-Module Dependencies
EP2323737A2 (en) 2008-08-08 2011-05-25 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
DE102008038221A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate
WO2010062861A2 (en) 2008-11-26 2010-06-03 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
DE102008059702A1 (de) 2008-12-01 2010-06-02 Byk-Chemie Gmbh Verfahren zur Herstellung rheologisch wirksamer Harnstoffurethane in organischen Salzen
WO2010139966A1 (en) 2009-06-05 2010-12-09 Oslo University Hospital Hf Azole derivatives as wtn pathway inhibitors
US20120238576A1 (en) 2009-06-08 2012-09-20 California Capital Equity, Llc Triazine Derivatives and their Therapeutical Applications
US8846739B2 (en) 2009-12-11 2014-09-30 Exelixis Patent Company Llc TGR5 agonists
KR101955691B1 (ko) 2010-03-30 2019-03-07 베르선 코포레이션 트롬빈 억제제로서의 다중치환된 방향족 화합물
WO2011133521A2 (en) 2010-04-19 2011-10-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
EP2560640A1 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
WO2011146801A1 (en) 2010-05-20 2011-11-24 Synta Pharmaceuticals Corp. Formulation and dosing of hsp90 inhibitory compounds
EP2995317A1 (en) 2010-05-26 2016-03-16 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
CN103140483B (zh) 2010-07-15 2015-06-24 拜耳知识产权有限责任公司 作为杀虫剂的新杂环化合物
WO2012021778A2 (en) 2010-08-12 2012-02-16 The Regents Of The University Of California Methods for blocking cell proliferation and treating diseases and conditions responsive to cell growth inhibition
US20130158063A1 (en) * 2010-08-24 2013-06-20 Georgetown University Compounds, Compositions and Methods Related to PPAR Antagonists
JP5517890B2 (ja) * 2010-11-15 2014-06-11 サンデン株式会社 ショーケース及び照明モジュール
WO2012076898A1 (en) * 2010-12-08 2012-06-14 Oslo University Hospital Hf Triazole derivatives as wnt signaling pathway inhibitors
US20140045908A1 (en) 2011-02-25 2014-02-13 Synta Pharmaceuticals Corp. Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers
WO2013020108A2 (en) 2011-08-04 2013-02-07 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of pancreatitis
WO2013032939A1 (en) 2011-08-26 2013-03-07 Metabolex, Inc. Bicyclic agonists of gpr131 and uses thereof
MX354242B (es) 2011-10-28 2018-02-20 Lumena Pharmaceuticals Inc Nhibidores de la recirculación de ácidos biliares para el tratamiento de enfermedades hepáticas colestásicas pediátricas.
CN107375291A (zh) 2011-10-28 2017-11-24 鲁美纳医药公司 用于治疗高胆血症和胆汁淤积性肝病的胆汁酸再循环抑制剂
CA2853806C (en) 2011-11-02 2020-07-14 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with platinum-containing agents
CA2853799A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
CA2854188A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
WO2013106437A1 (en) 2012-01-09 2013-07-18 Anchor Therapeutics, Inc. Apj receptor compounds
WO2013106614A1 (en) 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
EP2831061A1 (en) 2012-03-28 2015-02-04 Synta Pharmaceuticals Corp. Triazole derivatives as hsp90 inhibitors
US9957247B2 (en) 2012-06-07 2018-05-01 Georgia State University Research Foundation, Inc. SecA inhibitors and methods of making and using thereof
US20140005181A1 (en) * 2012-06-21 2014-01-02 Sanford-Burnham Medical Research Institute Small molecule antagonists of the apelin receptor for the treatment of disease
PL2897939T3 (pl) 2012-09-21 2017-08-31 Sanofi Pochodne amidu kwasu benzoimidazolo-karboksylowego do leczenia chorób metabolicznych i sercowo-naczyniowych
WO2014099984A1 (en) 2012-12-20 2014-06-26 Amgen Inc. Apj receptor agonists and uses thereof
BR112015023294A2 (pt) 2013-03-15 2017-07-18 Shifa Biomedical Corp método para tratamento ou prevenção de uma doença
UY35517A (es) 2013-04-04 2014-10-31 Mabxience S A Un procedimiento para aumentar la formación de ácido piroglutamico de una proteína
AU2014273962B2 (en) 2013-05-30 2019-07-25 Washington University Compounds and methods for treating bacterial infections
CA2942940A1 (en) 2014-03-20 2015-09-24 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of compounds inhibiting apelin / apj / gp130 signaling for treating cancer
EP3134427B1 (en) 2014-04-24 2020-06-03 Nanyang Technological University Asx-specific protein ligase
US10570128B2 (en) * 2014-05-28 2020-02-25 Sanford Burnham Prebys Medical Discovery Institute Agonists of the apelin receptor and methods of use thereof
WO2015188073A1 (en) 2014-06-06 2015-12-10 Research Triangle Institute Apelin receptor (apj) agonists and uses thereof
US20160058705A1 (en) 2014-08-28 2016-03-03 Jayakumar Rajadas Compositions and methods for treating cardiovascular and pulmonary diseases and disorders with apelin
HUE050317T2 (hu) * 2015-05-20 2020-11-30 Amgen Inc APJ receptor triazol agonistái
ES2739526T3 (es) 2015-06-03 2020-01-31 Bristol Myers Squibb Co Agonistas de APJ de 4-hidroxi-3-(heteroaril)piridin-2-ona para su uso en el tratamiento de trastornos cardiovaculares
EP3115826A1 (de) 2015-07-06 2017-01-11 Trumpf Laser Marking Systems AG Vorrichtung zur ablenkung eines laserstrahls
WO2017010058A1 (ja) 2015-07-14 2017-01-19 パナソニックＩｐマネジメント株式会社 識別媒体認識装置および識別媒体認識方法
CN108368087B (zh) 2015-10-14 2022-04-12 百时美施贵宝公司 作为apj激动剂的2，4-二羟基-烟酰胺
US10626096B2 (en) 2015-11-24 2020-04-21 Sanford Burnham Prebys Medical Discovery Institute Azole derivatives as apelin receptor agonist
US11390616B2 (en) 2015-12-04 2022-07-19 Bristol-Myers Squibb Company Apelin receptor agonists and methods of use
RU2021133849A (ru) 2015-12-09 2022-03-21 Рисерч Трайэнгл Инститьют Улучшенные агонисты апелинового рецептора (apj) и их использование
WO2017192485A1 (en) * 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor

Also Published As

Publication number Publication date
BR112017024618A2 (pt) 2018-11-13
US9745286B2 (en) 2017-08-29
US20170042871A1 (en) 2017-02-16
AR104716A1 (es) 2017-08-09
JP6356364B1 (ja) 2018-07-11
PT3300500T (pt) 2020-05-19
US10344016B2 (en) 2019-07-09
EP3300500B9 (en) 2021-01-13
HK1253366A1 (zh) 2019-06-14
CN108137545B (zh) 2020-09-22
ES2791315T3 (es) 2020-11-03
CA2985542C (en) 2023-10-10
US20190100510A1 (en) 2019-04-04
PH12017502107A1 (en) 2018-04-02
US9656998B2 (en) 2017-05-23
JP6055150B1 (ja) 2016-12-27
EA034776B1 (ru) 2020-03-19
CL2017002922A1 (es) 2018-03-16
KR20180011164A (ko) 2018-01-31
US20170042872A1 (en) 2017-02-16
JP2018524281A (ja) 2018-08-30
DK3300500T3 (da) 2020-05-18
EP3300500B1 (en) 2020-02-26
MA42145A (fr) 2018-04-04
AU2016263564B2 (en) 2019-12-05
EP3300500A1 (en) 2018-04-04
PL3300500T3 (pl) 2020-08-24
TN2017000483A1 (en) 2019-04-12
EA201792536A1 (ru) 2018-10-31
US20160340336A1 (en) 2016-11-24
MY193818A (en) 2022-10-27
US20170042897A1 (en) 2017-02-16
JP2017061546A (ja) 2017-03-30
MX2017014818A (es) 2018-02-09
CO2017012991A2 (es) 2018-03-28
LT3300500T (lt) 2020-05-25
US9868721B2 (en) 2018-01-16
TWI606039B (zh) 2017-11-21
JP2017036260A (ja) 2017-02-16
CY1123451T1 (el) 2022-03-24
CN108137545A (zh) 2018-06-08
RS60353B1 (sr) 2020-07-31
SI3300500T1 (sl) 2020-07-31
ME03733B (me) 2021-01-20
PE20180529A1 (es) 2018-03-19
ZA201707706B (en) 2022-11-30
UA119932C2 (uk) 2019-08-27
NZ737004A (en) 2022-10-28
US9573936B2 (en) 2017-02-21
US20180319773A1 (en) 2018-11-08
WO2016187308A1 (en) 2016-11-24
US10221162B2 (en) 2019-03-05
HUE050317T2 (hu) 2020-11-30
AU2016263564A1 (en) 2017-11-30
BR112017024618B1 (pt) 2023-03-14
IL255459A (en) 2018-01-31
KR102653667B1 (ko) 2024-04-03
US20170035744A1 (en) 2017-02-09
JP6130964B2 (ja) 2017-05-17
CA2985542A1 (en) 2016-11-24
UY36684A (es) 2016-12-30
MA42145B1 (fr) 2020-05-29
US9751864B2 (en) 2017-09-05
US9656997B2 (en) 2017-05-23
US20170281625A1 (en) 2017-10-05
US20170044131A1 (en) 2017-02-16
JO3653B1 (ar) 2020-08-27
US10058550B2 (en) 2018-08-28
US9845310B2 (en) 2017-12-19
TW201706248A (zh) 2017-02-16
US20170037026A1 (en) 2017-02-09

Similar Documents

Publication Publication Date Title
HRP20200690T1 (hr) Agonisti triazola apj receptora
AR075609A1 (es) Derivados pirazolicos heterociclicos nitrogenados activadores de guanilatociclasas solubles, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades cardiovasculares, entre otras.
HRP20161562T2 (hr) Derivati benzimidazola
HRP20220314T1 (hr) Spojevi n-((het)arilmetil)-heteroaril-karboksamida kao plazma kallikrein inhibitori
JP2019069940A (ja) スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用
HRP20200379T1 (hr) Spojevi pirimidindiona protiv srčanih stanja
RU2010150911A (ru) Амидное соединение
NL2000284C2 (nl) Pyrazine-derivaten.
AR073319A1 (es) Antagonistas de heteroarilo de receptores de prostaglandina d2
PE20190806A1 (es) Agonistas heterociclicos del receptor de apelina (apj) y usos de los mismos
Phillips et al. Discovery of trifluoromethyl (pyrimidin-2-yl) azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure–activity relationships, lead optimization, and chronic in vivo efficacy
IL259975A (en) Pyridine compounds are converted to 4-phenyl as unsystematic trg5 agonists
AR074089A1 (es) Antagonistas de cicloalcano (b) azaindol de los receptores de la postaglandina d2
RU2016108753A (ru) Ингибиторы ферментов
PE20190258A1 (es) Antagonistas del receptor de la apelina (apj) mejorados y usos de los mismos
AR050540A1 (es) Derivados de adamantilamida triciclica como inhibidores de deshidrogenasa 11- beta hidroxiesteroide
AR056688A1 (es) Derivados de la 4- amino - quinazolina su preparacion y su aplicacion en terapeutica
RU2014114466A (ru) ИНДАЗОЛ-3-КАРБОКСАМИДЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ СИГНАЛЬНОГО ПУТИ WNT/β-КАТЕНИНА
RU2014113926A (ru) АМИДОСОЕДИНЕНИЯ В КАЧЕСТВЕ RORγT МОДУЛЯТОРОВ И ИХ ПРИМЕНЕНИЕ
AR078536A1 (es) Derivados de pirazol como ligandos del receptor de estrogeno
PE20081472A1 (es) Compuestos de pirazolina
US20140018335A1 (en) Indole derivative, and pharmacologically acceptable salt thereof
AR063258A1 (es) Derivados de 2-aminocarbonil-piridina, una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento para el tratamiento de trastornos vasculares oclusivos.
AR065804A1 (es) Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
CA2982267C (en) Novel dgat2 inhibitors